Valuation: Inspire Medical Systems, Inc.

Capitalization 1.21B 1.03B 945M 893M 1.65B 116B 1.66B 11.25B 4.38B 54.86B 4.53B 4.44B 191B P/E ratio 2026 *
95.1x
P/E ratio 2027 * 34.5x
Enterprise value 1.05B 893M 818M 773M 1.43B 100B 1.44B 9.74B 3.79B 47.47B 3.92B 3.84B 165B EV / Sales 2026 *
1.24x
EV / Sales 2027 * 1.22x
Free-Float
98.74%
Yield 2026 *
-
Yield 2027 * -
1 day-4.86%
1 week-8.27%
Current month-25.33%
1 month-23.67%
3 months-29.85%
6 months-51.69%
Current year-54.55%
1 week 41.55
Extreme 41.5501
45.72
1 month 41.55
Extreme 41.5501
58.98
Current year 41.55
Extreme 41.5501
102.64
1 year 41.55
Extreme 41.5501
156.82
3 years 41.55
Extreme 41.5501
330
5 years 41.55
Extreme 41.5501
330
10 years 22.5
Extreme 22.5
330
Manager TitleAgeSince
Chief Executive Officer 63 2007-10-31
Director of Finance/CFO 50 2026-01-18
Chief Operating Officer 46 -
Director TitleAgeSince
Chairman 63 2024-05-01
Director/Board Member 66 2008-06-30
Director/Board Member 68 2006-12-31
Change 5d. change 1-year change 3-years change Capi.($)
-4.86%-8.27%-73.76%-85.74% 1.21B
+2.59%+3.34%-22.05%+5.82% 116B
-0.18%-0.90%+4.50%-14.05% 12.73B
+0.68%+1.49%+48.65%+133.45% 8.06B
+3.94%+3.55%-30.12%-66.90% 5.32B
+0.49%-4.32%+6.49%+28.17% 2.47B
+2.47%+2.44%-8.22%-8.90% 2.06B
+1.20%+5.58%+23.35%-4.53% 1.89B
-1.12%+3.42%-31.19%-54.54% 1.48B
Average +0.58%+0.39%-9.15%-7.47% 16.78B
Weighted average by Cap. +2.15%+2.60%-15.60%+7.11%

Financials

2026 *2027 *
Net sales 843M 720M 660M 624M 1.15B 80.67B 1.16B 7.85B 3.06B 38.28B 3.16B 3.1B 133B 877M 749M 686M 649M 1.2B 83.92B 1.21B 8.17B 3.18B 39.83B 3.29B 3.22B 138B
Net income 15.28M 13.05M 11.96M 11.3M 20.93M 1.46B 21.04M 142M 55.43M 694M 57.34M 56.14M 2.41B 36.21M 30.92M 28.33M 26.79M 49.6M 3.47B 49.86M 337M 131M 1.64B 136M 133M 5.72B
Net Debt -163M -139M -127M -120M -223M -15.56B -224M -1.51B -590M -7.38B -610M -597M -25.67B -140M -120M -110M -104M -192M -13.44B -193M -1.31B -510M -6.38B -527M -516M -22.17B
Logo Inspire Medical Systems, Inc.
Inspire Medical Systems, Inc. is a medical technology company. The Company focuses on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is neurostimulation technology that provides safe and effective treatment for moderate to severe obstructive sleep apnea. The Company's closed-loop solution continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.
Employees
1,333
Date Price Change Volume
26-05-13 41.92 $ -4.86% 1,142,242
26-05-12 44.06 $ +1.64% 969,872
26-05-11 43.35 $ -2.06% 926,871
26-05-08 44.26 $ -2.87% 971,774
26-05-07 45.57 $ -0.28% 2,005,805
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
41.92USD
Average target price
53.33USD
Spread / Average Target
+27.23%

Quarterly revenue - Rate of surprise